J Vet Sci.  2013 Dec;14(4):467-472. 10.4142/jvs.2013.14.4.467.

Development of a novel enzyme-linked immunosorbent assay to detect anti-IgG against swine hepatitis E virus

• Lee WJ
• Shin MK
• Cha SB
• Yoo HS

• KMID: 1712314
• DOI: http://doi.org/10.4142/jvs.2013.14.4.467

Abstract

Swine hepatitis E virus (HEV) is widespread throughout pigs in both developing and industrialized countries. This virus is an important zoonotic agent and a public concern worldwide. Infected pigs are asymptomatic, so diagnosing swine HEV relies on detection of the virus or antibodies against the virus. However, several obstacles need to be overcome for effective and practical serological diagnosis. In this study, we developed an enzyme-linked immunosorbent assay (ELISA) that used a purified recombinant capsid protein of swine HEV. The potential clinical use of this assay was evaluated by comparing it with a commercial kit (Genelabs Technologies, Diagnostics, Singapore). Results of the ELISA were highly correlated with those of the commercial kit with a sensitivity of 97% and specificity of 95%. ROC (receiving operator characteristic) analysis of the ELISA data produced a value of 0.987 (95% CI, 0.977~0.998, p < 0.01). The cut-off value for the ELISA was also determined using negative pig sera. In summary, the HEV-specific ELISA developed in the present study appears to be both practical and economical.

Keyword

diagnosis; ELISA; swine hepatitis E virus

MeSH Terms

Animals
Antibodies, Anti-Idiotypic/*analysis/blood/genetics
Capsid Proteins/*genetics/metabolism
Enzyme-Linked Immunosorbent Assay/*methods/veterinary
Hepatitis E/diagnosis/immunology/*veterinary/virology
Hepatitis E virus/genetics/*isolation & purification/metabolism
Immunoglobulin G/blood/genetics
ROC Curve
Recombinant Proteins/genetics/metabolism
Swine
Swine Diseases/*diagnosis/immunology/virology
Antibodies, Anti-Idiotypic
Capsid Proteins
Immunoglobulin G
Recombinant Proteins

Figure

• 

  Fig. 1 Purification of the recombinant capsid protein of swine HEV. The recombinant capsid protein was analyzed by SDS-PAGE (A and C) and Western blotting with an anti-HEV monoclonal antibody (B). Western blotting with HEV-positive pig serum was also performed (D). Lane M: prestained protein molecular mass marker (kDa), lanes 1-4, and 6: induced capsid protein, lane 5: uninduced capsid protein.

• 

  Fig. 2 Determination of the optimal antigen concentration (recombinant capsid protein) for the developed ELISA. A two-fold dilution series of the recombinant capsid protein was performed to identify the optimum concentration of the recombinant protein, and a titration experiment was performed using pig sera already known to be HEV-positive. Results of the checkerboard titration analysis demonstrated that the most optimal and reliable results were obtained when each microplate well was coated with 1.25 µg/mL of the capsid protein.

• 

  Fig. 3 Receiver operating characteristics (ROC) analysis of the developed ELISA. The area under the ROC curve (AUC) of the developed ELISA was 0.987 (95% CI, 0.977~0.998; p < 0.001). The blue line represents the test curve and the green line corresponds to the non-informative test curve. Sensitivity and specificity of the developed ELISA were 97% and 95%, respectively, when the optimal cut-off OD value was 0.6.

• 

  Fig. 4 Correlation between the results of the developed ELISA and a commercial kit for 235 field-collected pig sera samples. After the 235 pig sera were tested with the HEV-specific commercial ELISA kit, the same 235 samples were subjected analysis with the developed ELISA test. The correlation ratio (R2) between the developed ELISA and the commercial kit results was 0.717.

Reference

1. Aggarwal R. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013; 10:24–33.

2. Ahn JM, Kang SG, Lee DY, Shin SJ, Yoo HS. Identification of novel human hepatitis E virus (HEV) isolates and determination of the seroprevalence of HEV in Korea. J Clin Microbiol. 2005; 43:3042–3048.

3. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, Purcell RH. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis. 1995; 171:447–450.

4. Choi IS, Kwon HJ, Shin NR, Yoo HS. Identification of swine hepatitis E virus (HEV) and prevalence of anti-HEV antibodies in swine and human populations in Korea. J Clin Microbiol. 2003; 41:3602–3608.

5. Clemente-Casares P, Pina S, Buti M, Jardi R, Martín M, Bofill-Mas S, Girones R. Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis. 2003; 9:448–454.

6. Crowther JR. The ELISA guidebook. Methods Mol Biol. 2000; 149:III–IIV. 1–413.

7. Daniel HDJ, Warier A, Abraham P, Sridharan G. Age-wise exposure rates to hepatitis E virus in a southern Indian patient population without liver disease. Am J Trop Med Hyg. 2004; 71:675–678.

8. Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious Hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol. 2007; 88:912–917.

9. Fosgate GT, Scott HM, Jordan ER. Development of a method for Bayesian nonparametric ROC analysis with application to an ELISA for John's disease in dairy cattle. Prev Vet Med. 2007; 81:178–193.

10. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998; 221:35–41.

11. Graff J, Zhou YH, Torian U, Nguyen H, St. Claire M, Yu C, Purcell RH, Emerson SU. Claire M, Yu C, Purcell RH, Emerson SU. Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J Virol. 2008; 82:1185–1194.

12. Greiner M, Sohr D, Göbel P. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. J Immunol Methods. 1995; 185:123–132.

13. Halbur PG, Kasorndorkbua C, Gilbert C, Guenette D, Potters MB, Purcell RH, Emerson SU, Toth TE, Meng XJ. Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human. J Clin Microbiol. 2001; 39:918–923.

14. Herremans M, Bakker J, Duizer E, Vennema H, Koopmans MPG. Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity. Clin Vaccine Immunol. 2007; 14:562–568.

15. Lee WJ, Kang ML, Cha SB, Park BK, Choi IS, Yoo HS. Analysis of the helicase gene of Korean swine hepatitis E virus isolates and trends in viral infection. Arch Virol. 2009; 154:1361–1364.

16. Lee WJ, Yoo HS. Hepatitis E: Morphology, Pathogenesis and Prevention. In : Berhardt LV, editor. Advances in Medicine and Biology. New York: NOVA Science Publishers;2012. Vol. 39:p. 149–165.

17. Li SW, Zhang J, He ZQ, Gu Y, Liu RS, Lin J, Chen YX, Ng MH, Xia NS. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem. 2005; 280:3400–3406.

18. Meng XJ. Hepatitis E virus: animal reservoirs and zoonotic risk. Vet Microbiol. 2010; 140:256–265.

19. Meng XJ. Swine hepatitis E virus: cross-species infection and risk in xenotransplantation. Curr Top Microbiol Immunol. 2003; 278:185–216.

20. Meng XJ, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS, Haynes JS, Thacker BJ, Emerson SU. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A. 1997; 94:9860–9865.

21. Myint KS, Endy TP, Gibbons RV, Laras K, Mammen MP Jr, Sedyaningsih ER, Seriwatana J, Glass JS, Narupiti S, Corwin AL. Evaluation of diagnostic assays for hepatitis E virus in outbreak settings. J Clin Microbiol. 2006; 44:1581–1583.

22. de Niet A, Zaaijer HL, ten Berge I, Weegink CJ, Reesink HW, Beuers U. Chronic hepatitis E after solid organ transplantation. Neth J Med. 2012; 70:261–266.

23. Park HK, Jeong SH, Kim JW, Woo BH, Lee DH, Kim HY, Ahn S. Seroprevalence of anti-hepatitis E virus (HEV) in a Korean population: comparison of two commercial anti-HEV assays. BMC Infect Dis. 2012; 12:142.

24. Surjit M, Jameel S, Lal SK. The ORF2 protein of hepatitis E virus binds the 5' region of viral RNA. J Virol. 2004; 78:320–328.

25. Worm HC, van der, Brandstätter G. Hepatitis E: an overview. Microbes Infect. 2002; 4:657–666.

26. Zhang H, Dai X, Shan X, Meng J. The Leu477 and Leu613 of ORF2-encoded protein are critical in forming neutralization antigenic epitope of hepatitis E virus genotype 4. Cell Mol Immunol. 2008; 5:447–456.

27. Zhang JZ, Im SWK, Lau SH, Chau TN, Lai ST, Ng SP, Peiris M, Tse C, Ng TK, Ng MH. Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. J Med Virol. 2002; 66:40–48.